The purpose of the study is to evaluate the significance of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the clinical diagnostic criteria and other respiratory diseases. In addition, the study discusses the value of KL-6 levels in terms of ILD treatment effect evaluation through the detection of serum KL-6 levels before treatment and after treatment.
As a multi-center, double-blind clinical study, the trial is divided into two parts. Part 1: The purpose of this part is to evaluate the role of KL-6 as a biomarker in the clinical diagnosis of interstitial lung disease (ILD) by detecting serum KL-6 levels among patients with ILD, and comparing them to the clinical diagnostic criteria and other respiratory diseases, including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease and healthy control group. Part 2: The purpose of this part is to study the value of KL-6 levels in terms of ILD treatment effect evaluation through the detection of serum KL-6 levels before treatment and 30-90 days after treatment. Treatment includes anti fibrosis, anti-inflammatory and other conventional therapies.
Study Type
OBSERVATIONAL
Enrollment
1,190
The KL-6 concentration on the immune analyzer
Detect the KL-6 concentration in serum by the use of the immune analyzer among patients with ILD.
Time frame: The serum from patients with ILD will be collected for the duration of hospital stay, an average of 4 weeks
The KL-6 concentration on the immune analyzer
Detect the KL-6 concentration in serum by the use of the immune analyzer among patients with other respiratory diseases, including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease.
Time frame: The serum from patients other respiratory diseases will be collected for the duration of hospital stay, an average of 4 weeks
The KL-6 concentration on the immune analyzer
Detect the KL-6 concentration in serum by the use of the immune analyzer among healthy people.
Time frame: The serum from healthy people will be collected for the duration of physical examination, an average of 1 day
Change of KL-6 concentration on the immune analyzer
Change of KL-6 concentration on the immune analyzer from pretherapy to 30-90 days after treatment among patients with ILD.
Time frame: pretherapy, 30-90 days after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.